Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: A prospective clinical study with 12 months follow-up

Supportive Care in Cancer

Volumn 18, Issue 4, 2010, Pages 449-460

  Stockmann, Philipp ^a   Vairaktaris, Eleftherios ^b   Wehrhan, Falk ^a   Seiss, Martin ^a   Schwarz, Stephan ^a   Spriewald, Bernd ^a   Neukam, Friedrich Wilhelm ^a   Nkenke, Emeka ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bisphosphonate; Bisphosphonate associated osteonecrosis; Osteotomy; Prospective study; Surgical treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE UNIT; JAW OSTEONECROSIS; MALE; OSTEOPOROSIS; OSTEOTOMY; PATIENT MONITORING; PLASMACYTOMA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT RESPONSE; WOUND CLOSURE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; JAW DISEASE; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; REOPERATION; SUTURING METHOD; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; OSTEOTOMY; PLASMACYTOMA; PROSPECTIVE STUDIES; RECURRENCE; REOPERATION; SUTURE TECHNIQUES; TREATMENT OUTCOME;

EID: 77952503639     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0688-1     Document Type: Article

References (40)

1. AAOMS (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369-376
2. Adornato MC, Morcos I, Rozanski J (2007) The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 138:971-977
3. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G (2007) Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 18:1071-1075 (Pubitemid 47524914)
4. Biasotto M, Chiandussi S, Dore F, Rinaldi A, Rizzardi C, Cavalli F, Di Lenarda R (2006) Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws. Acta Odontol Scand 64:348-354 (Pubitemid 44845517)
5. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
6. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857-869
7. Carter GD, Goss AN (2003) Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48:268
8. Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736-1740
9. Greenberg MS (2004) Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:259-260
10. Groetz KA, Al-Nawas B (2006) Persisting alveolar sockets-a radiologic symptom of BP-ONJ? J Oral Maxillofac Surg 64:1571-1572
11. Grotz KA, Kreusch T (2006) Zahnärztliche Betreuung von Patienten unter/nach Bisphosphonat-Medikation (Wissenschaftliche Stellungnahme der DGZMK, AG Kieferchirurgie und DGMKG). Dtsch Zahnärztl Z 61:510-513
12. Harper RP, Fung E (2007) Resolution of bisphosphonateassociated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65:573-580
13. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826-836
14. Kademani D, Koka S, Lacy MQ, Rajkumar SV (2006) Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81:1100-1103
15. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonateassociated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491
16. Klingemann HG, Egbring R, Havemann K (1981) Incomplete fibrin formation and highly elevated Factor XIII activity in multiple myeloma. Scand J Haematol 27:253-262
17. Lamboley V, Zabraniecki L, Sie P, Pourrat J, Fournie B (2002) Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review. Jt Bone Spine 69:62-67
18. Lee MV, Fong EM, Singer FR, Guenette RS (2001) Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602-2608
19. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-1117
20. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-1575
21. Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D'Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P (2006) Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twentynine cases. Acta Biomed 77:109-117
22. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB (2005) Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136:1658-1668
23. Montebugnoli L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, Marchetti C (2007) Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:473-477
24. Nkenke E, Schultze-Mosgau S, Radespiel-Troger M, Kloss F, Neukam FW (2001) Morbidity of harvesting of chin grafts: a prospective study. Clin Oral Implants Res 12:495-502
25. Petrucci MT, Gallucci C, Agrillo A, Mustazza MC, Foa R (2007) Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica 92:1289-1290
26. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, Auriola S, Chilton KM, Russell RG (1999) Molecular mechanisms of action of bisphosphonates. Bone 24:73S-79S
27. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157
28. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534
29. Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(Suppl 2):S66-S80
30. Sarin J, Derossi SS, Akintoye SO (2008) Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14:277-285
31. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459-1468
32. Shimura K, Shimazaki C, Taniguchi K, Akamatsu S, Okamoto M, Uchida R, Nomura K, Inaba T, Horiike S, Kanamura N, Taniwaki M (2006) Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 84:343-345
33. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98:665-672
34. Tarassoff P, Csermak K (2003) Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61:1238-1239
35. Van den Wyngaert T, Huizing MT, Vermorken JB (2007) Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 19:315-322
36. Vescovi P, Merigo E, Meleti M, Fornaini C, Nammour S, Manfredi M (2007) Nd:YAG laser biostimulation of bisphosphonate-associated necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg 45:628-632
37. Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104-1107
38. Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761
39. Wutzl A, Biedermann E, Wanschitz F, Seemann R, Klug C, Baumann A, Watzinger F, Schicho K, Ewers R, Millesi G (2008) Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30:1224-1230
40. Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A (2006) Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 118:473-478